Literature DB >> 27490639

Associations between antiretroviral use and subclinical coronary atherosclerosis.

Guajira P Thomas1, Xiuhong Li, Wendy S Post, Lisa P Jacobson, Mallory D Witt, Todd T Brown, Lawrence A Kingsley, John P Phair, Frank J Palella.   

Abstract

OBJECTIVES: HIV infection is associated with increased prevalence of subclinical coronary plaque. The extent to which such plaque reflects effects of HIV infection or effects of long-term antiretroviral therapy (ART) use remains unclear and was the goal of this analysis. DESIGN AND METHODS: We compared the prevalence and extent of coronary plaque and stenosis between users of specific ART drugs or drug classes using coronary computed tomography (CT) among HIV-infected men in the Multicenter AIDS Cohort Study. To account for time-dependent confounders, including cardiovascular disease risk factors and time-varying reasons for using specific treatments, we conducted fully adjusted logistic and linear models with inverse probability of treatment weighting.
RESULTS: There were 618 men who underwent noncontrast coronary CT; 450 also underwent coronary CT angiography. At the time of scanning, 81% had undetectable plasma HIV RNA. In fully adjusted models, cumulative use of zidovudine, abacavir, darunavir, and protease inhibitors as a drug class were inconsistently associated with specific forms of plaque presence or extent.
CONCLUSION: Among virally suppressed HIV-infected men with extensive ART exposure, no consistent associations between use of specific ART drugs and both subclinical coronary plaque presence and extent were apparent. Our findings support the hypothesis that, among virally suppressed persons, type of ART used is not in general a major determinant of subclinical coronary plaque risk.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27490639      PMCID: PMC5173385          DOI: 10.1097/QAD.0000000000001220

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  33 in total

1.  Associations between HIV infection and subclinical coronary atherosclerosis.

Authors:  Wendy S Post; Matthew Budoff; Lawrence Kingsley; Frank J Palella; Mallory D Witt; Xiuhong Li; Richard T George; Todd T Brown; Lisa P Jacobson
Journal:  Ann Intern Med       Date:  2014-04-01       Impact factor: 25.391

Review 2.  HIV infection, inflammation, immunosenescence, and aging.

Authors:  Steven G Deeks
Journal:  Annu Rev Med       Date:  2011       Impact factor: 13.739

3.  Quantification of coronary artery calcium using ultrafast computed tomography.

Authors:  A S Agatston; W R Janowitz; F J Hildner; N R Zusmer; M Viamonte; R Detrano
Journal:  J Am Coll Cardiol       Date:  1990-03-15       Impact factor: 24.094

Review 4.  Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance.

Authors:  A Carr; K Samaras; D J Chisholm; D A Cooper
Journal:  Lancet       Date:  1998-06-20       Impact factor: 79.321

5.  A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy.

Authors:  T Saint-Marc; M Partisani; I Poizot-Martin; F Bruno; O Rouviere; J M Lang; J A Gastaut; J L Touraine
Journal:  AIDS       Date:  1999-09-10       Impact factor: 4.177

6.  Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study.

Authors:  Frank J Palella; Stephen J Gange; Lorie Benning; Lisa Jacobson; Robert C Kaplan; Alan L Landay; Russell P Tracy; Richard Elion
Journal:  AIDS       Date:  2010-07-17       Impact factor: 4.177

7.  HIV infection and the risk of acute myocardial infarction.

Authors:  Matthew S Freiberg; Chung-Chou H Chang; Lewis H Kuller; Melissa Skanderson; Elliott Lowy; Kevin L Kraemer; Adeel A Butt; Matthew Bidwell Goetz; David Leaf; Kris Ann Oursler; David Rimland; Maria Rodriguez Barradas; Sheldon Brown; Cynthia Gibert; Kathy McGinnis; Kristina Crothers; Jason Sico; Heidi Crane; Alberta Warner; Stephen Gottlieb; John Gottdiener; Russell P Tracy; Matthew Budoff; Courtney Watson; Kaku A Armah; Donna Doebler; Kendall Bryant; Amy C Justice
Journal:  JAMA Intern Med       Date:  2013-04-22       Impact factor: 21.873

8.  Use of cardiac CT angiography imaging in an epidemiology study - the Methodology of the Multicenter AIDS Cohort Study cardiovascular disease substudy.

Authors:  Yalçın Hacıoğlu; Mohit Gupta; Tae Young Choi; Richard T George; Christopher R Deible; Lisa P Jacobson; Mallory D Witt; Frank J Palella; Wendy S Post; Matthew J Budoff
Journal:  Anadolu Kardiyol Derg       Date:  2013-01-30

9.  Class of antiretroviral drugs and the risk of myocardial infarction.

Authors:  Nina Friis-Møller; Peter Reiss; Caroline A Sabin; Rainer Weber; Antonella d'Arminio Monforte; Wafaa El-Sadr; Rodolphe Thiébaut; Stephane De Wit; Ole Kirk; Eric Fontas; Matthew G Law; Andrew Phillips; Jens D Lundgren
Journal:  N Engl J Med       Date:  2007-04-26       Impact factor: 91.245

10.  Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.

Authors:  Signe Westring Worm; Caroline Sabin; Rainer Weber; Peter Reiss; Wafaa El-Sadr; Francois Dabis; Stephane De Wit; Matthew Law; Antonella D'Arminio Monforte; Nina Friis-Møller; Ole Kirk; Eric Fontas; Ian Weller; Andrew Phillips; Jens Lundgren
Journal:  J Infect Dis       Date:  2010-02-01       Impact factor: 5.226

View more
  7 in total

1.  Associations between lipids and subclinical coronary atherosclerosis.

Authors:  Seamus P Whelton; Jennifer A Deal; Michelle Zikusoka; Lisa P Jacobson; Sudipa Sarkar; Frank J Palella; Lawrence Kingsley; Matthew Budoff; Mallory D Witt; Todd T Brown; Wendy S Post
Journal:  AIDS       Date:  2019-05-01       Impact factor: 4.177

Review 2.  HIV infection and coronary heart disease: mechanisms and management.

Authors:  Priscilla Y Hsue; David D Waters
Journal:  Nat Rev Cardiol       Date:  2019-06-10       Impact factor: 32.419

3.  Positive Expression of Human Cytomegalovirus Phosphoprotein 65 in Atherosclerosis.

Authors:  Zhe Wang; Jun Cai; Mingming Zhang; Xiaojing Wang; Hongjie Chi; Haijun Feng; Xinchun Yang
Journal:  Biomed Res Int       Date:  2016-11-20       Impact factor: 3.411

4.  Assessment of Coronary Artery Disease With Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers Among Adults With HIV Eligible for Primary Cardiovascular Prevention.

Authors:  Udo Hoffmann; Michael T Lu; Borek Foldyna; Markella V Zanni; Julia Karady; Jana Taron; Bingxue K Zhai; Tricia Burdo; Kathleen V Fitch; Emma M Kileel; Kenneth Williams; Carl J Fichtenbaum; Edgar T Overton; Carlos Malvestutto; Judith Aberg; Judith Currier; Craig A Sponseller; Kathleen Melbourne; Michelle Floris-Moore; Cornelius Van Dam; Michael C Keefer; Susan L Koletar; Pamela S Douglas; Heather Ribaudo; Thomas Mayrhofer; Steven K Grinspoon
Journal:  JAMA Netw Open       Date:  2021-06-01

5.  Abacavir Use and Risk for Myocardial Infarction and Cardiovascular Events: Pooled Analysis of Data From Clinical Trials.

Authors:  Cassandra Nan; Mark Shaefer; Rimgaile Urbaityte; James Oyee; Judy Hopking; Leigh Ragone; Teodora Perger; Beta Win; Harald Vangerow; Cynthia McCoig; Vani Vannappagari
Journal:  Open Forum Infect Dis       Date:  2018-04-20       Impact factor: 3.835

Review 6.  A Review of Long-Term Toxicity of Antiretroviral Treatment Regimens and Implications for an Aging Population.

Authors:  Anita Chawla; Christina Wang; Cody Patton; Miranda Murray; Yogesh Punekar; Annemiek de Ruiter; Corklin Steinhart
Journal:  Infect Dis Ther       Date:  2018-05-14

7.  Abacavir antiretroviral therapy and indices of subclinical vascular disease in persons with HIV.

Authors:  Claudia A Martinez; Rishi Rikhi; Mollie S Pester; Meela Parker; Alex Gonzalez; Michaela Larson; Jennifer Chavez; Armando Mendez; Jeffrey K Raines; Michael A Kolber; Ivonne H Schulman; Maria L Alcaide; Barry E Hurwitz
Journal:  PLoS One       Date:  2022-03-10       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.